About Cytocybernetics
Cytocybernetics is a company based in Buffalo (United States) founded in 2013. Cytocybernetics offers products and services including Cybercyte Dynamic Clamp, Cytovolt Voltage-Sensitive Dyes, Cybersolver Model Builder, CyberQ, and MP 500 Pipette Puller. Cytocybernetics operates in a competitive market with competitors including PD Neurotechnology, Novoheart, Winterlight Labs, Quiver Bioscience and Forcyte Biotechnologies, among others.
- Headquarter Buffalo, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cytocybernetics.com
- Social LinkedIn X YouTube
- Latest Funding Round$256.58K (USD), Grant
Jul 2022
- InvestorsHHS
& 2 more
Products & Services of Cytocybernetics
Cytocybernetics offers a comprehensive portfolio of products and services, including Cybercyte Dynamic Clamp, Cytovolt Voltage-Sensitive Dyes, Cybersolver Model Builder, CyberQ, and MP 500 Pipette Puller.
Plug-and-play system for simulating ion channels in labs.
Dyes providing up to four hours of voltage sensitivity.
Drag-and-drop interface for building electrophysiology models.
Software for rapid FDA qNET metric calculations.
Device for preparing pipettes in electrophysiology setups.
Tailored solutions for electrophysiology research needs.
Apps and channels of Cytocybernetics
its YouTube channel Cytocybernetics has 2 subscribers and 2 videos.
Videos from Cytocybernetics
The most watched videos on Cytocybernetics's YouTube channel, Cytocybernetics (2 subscribers). Click a video to play it here.
More on Cytocybernetics.
Funding Insights of Cytocybernetics
- Total Rounds 6
- Last Round Grant — $256,581
- First Round $1.73M
(Jul 2015)
- Investors Count 3
All 6 funding rounds of Cytocybernetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
3 investors in total: 3 institutional.
Investors in Cytocybernetics
Cytocybernetics has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, America’s Seed Fund and 43North.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund backed by the US Government | – | seedfund.nsf.gov | Alexandria, United States | |
Seed-stage investments are targeted by 43North in startups. | – | 43north.org | Buffalo, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - |
Investor details for Cytocybernetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Cytocybernetics
1 people are tracked at Cytocybernetics (1 in leadership).
| Name | Role | Group |
|---|---|---|
Glenna Bett | CEO | Leadership |
Complete people profiles for Cytocybernetics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Cytocybernetics
3 dated milestones of Cytocybernetics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Cytocybernetics is founded.
- Funding First funding round of $1.7M.
- Funding Latest funding round, Grant, of $257K.
Competitors of Cytocybernetics
Cytocybernetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PD Neurotechnology, Novoheart, Winterlight Labs, Quiver Bioscience and Forcyte Biotechnologies, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pdneurotechnology.com | 2015 | London, United Kingdom | $93.34M | 32 | A wearable device is developed to monitor Parkinson's movement disorders. | |
| novoheart.com | 2014 | Vancouver, Canada | – | – | Bioartificial hearts are engineered using stem cells and tissue methods. | |
| winterlightlabs.com | 2015 | Toronto, Canada | $5.73M | – | Cognitive impairment signs are detected through speech sample analysis. | |
| quiverbioscience.com | 2013 | Cambridge, United States | – | – | Developer of transformational medicines for neurological disorders | |
| forcytebio.com | 2017 | Los Angeles, United States | $1.13M | – | Automated single-cell contractility screening systems are developed for drug discovery. | |
| multichannelsystems.com | 1996 | Reutlingen, Germany | – | 68 | Tools and systems for electrophysiology are developed and supplied. | |
| functionalfluidics.com | 2013 | Detroit, United States | $3.58M | – | Microfluidics-based assays are developed for studying blood disorders. | |
| localite.de | 1999 | Bonn, Germany | – | 15 | Surgical navigation systems for medical procedures are developed. | |
| mxwbio.com | 2016 | Basel, Switzerland | $4.64M | – | In vitro electrophysiology platform for electrogenic cell analysis is developed. |
Detailed competitors of Cytocybernetics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Cytocybernetics
10 companies that operate in the same segment as Cytocybernetics (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cytocybernetics
Cytocybernetics was founded in 2013 and raised its 1st funding round 2 years after it was founded.
Cytocybernetics is headquartered in Buffalo, United States. It is registered at Buffalo, New York, United States.
Cytocybernetics was founded in 2013 in Buffalo, United States, within the biotechnology sector. Tools for electrophysiology research are developed, with a portfolio that includes patch clamp systems and dynamic clamp technology. Services provided encompass drug safety screening, custom electrophysiology experiments, tailored modeling, and specialized data analysis, supporting operations in scientific and pharmaceutical applications.
Cytocybernetics's top competitors include Quiver Bioscience, Novoheart and PD Neurotechnology.
Cytocybernetics offers Cybercyte Dynamic Clamp, Cytovolt Voltage-Sensitive Dyes, Cybersolver Model Builder, CyberQ, and 2 more products and services.
Cytocybernetics has 3 investors. Key investors include HHS, America’s Seed Fund, and 43North.